The FILM Study (NCT 02209532) was a randomized, prospective, multi-center, open-label study in patients with early stage uterine or cervical cancer and no known regional nodal or metastatic disease by standard clinical evaluation. SPY AGENT GREEN and a blue dye comparator were injected into the cervix of patients at the beginning of the operative procedure.
A total of 176 patients were randomized to receive either SPY AGENT GREEN followed by blue dye or blue dye followed by SPY AGENT GREEN. Four 1 mL injections of a 1.25 mg/mL solution of SPY AGENT GREEN for a total dose of 5 mg were administered interstitially into the cervix at the 3 o’clock and 9 o’clock positions with a superficial (1 mm to 3 mm) and a deep (1 cm to 3 cm) injection at each position.
Lymphatic mapping was performed intraoperatively using the PINPOINT® Fluorescence Imaging System and standard light, followed by excision of tissues identified by SPY AGENT GREEN, blue dye, or the surgeon’s visual and palpation examination. The resected tissues were evaluated by histopathology to confirm presence of lymph nodes. The efficacy of SPY AGENT GREEN and the PINPOINT® Fluorescence Imaging System in the detection of lymphatic vessels and lymph nodes during lymphatic mapping procedures was determined by the number of histology-confirmed lymph nodes detected by SPY AGENT GREEN and/or the blue dye comparator.
The mean age of the 176 patients was 63 years (range: 31 to 88 years); distribution by race and ethnicity was 79% White, 4% Black or African American, 3% Asian, 13% Hispanic/Latino and 1% other.
Table 1 shows the distribution of resected, confirmed lymph nodes detected by SPY AGENT GREEN or blue dye in the modified intent-to-treat population (mITT). Among the confirmed lymph nodes identified, 93% were identified using SPY AGENT GREEN, and 43% were identified using blue dye, a difference of 50% [95% confidence interval 39% to 60%].
Table 1: Distribution of Resected Confirmed Lymph Nodes Detected by SPY AGENT GREEN or Blue Dye (BD)Analysis Population | Nodes (n) | All Lymph Nodes Detected with SPY AGENT GREEN | All Lymph Nodes Detected with BD | Lymph Nodes Detected with SPY AGENT GREEN Only | Lymph Nodes Detected with BD Only | Lymph Nodes Detected with Neither |
| mITT | 513 | (476/513) 93% | (220/513) 43% | (262/513) 51% | (6/513) 1% | (31/513) 6% |
Table 2 shows the number of patients with at least one resected, confirmed lymph node and the number of patients with at least one bilateral lymph node pair detected by SPY AGENT GREEN or blue dye. With SPY AGENT GREEN, approximately 97% of patients had at least one resected, confirmed lymph node detected and 73% had at least one bilateral lymph node pair detected, compared with 68% and 28%, respectively, with blue dye [p-values for each analysis <0.0001].
Table 2: Distribution of Patients with at Least One Confirmed Unilateral Lymph Node / Bilateral Pair Detected by SPY AGENT GREEN or Blue Dye (BD)*: patients with at least one resected confirmed lymph node detected unilaterally **: patients with at least one resected confirmed lymph node detected bilaterally |
Analysis Population | Patients (n) | Patients with All Lymph Nodes Detected with SPY AGENT GREEN | Patients with All Lymph Nodes Detected with BD | Patients with Lymph Nodes Detected with SPY AGENT GREEN Only | Patients with Lymph Nodes Detected with BD Only | Patients with Lymph Nodes Detected with Neither |
mITT Unilateral* | 172 | (167/172) 97% | (118/172) 68% | (51/172) 30% | (2/172) 1% | (3/172) 3% |
| mITT Bilateral** | (126/172) 73% | (49/172) 28% | (79/172) 46% | (2/172) 1% | (44/172) 26% |